Skip to main content
OpenTrials
Completed

NCT Number: NCT01499680

Multimodality Neuromonitoring in XLIF

This is a prospective, non-randomized multi-center study to evaluate intraoperative neuromonitoring results in subjects who undergo eXtreme Lateral Interbody Fusion (XLIF) surgery at any number of levels inclusive of L4-5.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Caribbean Orthopaedic and Spine Institute, San Juan, PR, Puerto Rico

Loading trial locations.

About this study

Subjects will present with degenerative conditions in the lumbar spine that are amenable to surgical treatment and will be screened prior to study enrollment. Subjects will undergo neuromonitoring during the XLIF operation, as per standard care. They will then be re-evaluated immediately after surgery and at the first standard postoperative follow-up visit (6 weeks) to assess for presence of new neural deficit. If a new neural deficit is identified, the patient will be followed per the Investigator's standard follow-up schedule until symptoms have resolved (or are deemed permanent).

A total of 300 subjects will be enrolled in this study from multiple centers. The subjects will have degenerative conditions of the lumbar spine with planned treatment including XLIF surgery. The following eligibility criteria are designed to identify existing clinic patients for whom study under this protocol is considered appropriate. All subjects must meet the inclusion/exclusion criteria below in order to be considered for enrollment.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Persistent back and/or leg pain unresponsive to conservative treatment for at least six (6) months, unless surgical treatment is clinically indicated earlier
  • Indicated for extreme lateral interbody fusion at any number of levels inclusive of L4-5
  • At least 18 years of age at the date of written informed consent
  • Able to undergo surgery based on physical exam, medical history and surgeon judgment
  • Willing and able to return for post-treatment exams according to the follow-up called for in the protocol
  • Signed and dated informed consent form

Exclusion criteria

  • Patient has a mental or physical condition that would limit the ability to comply with study requirements
  • Patient is a prisoner
  • Patient is involved in active litigation relating to the spine (worker's compensation claim is allowed if it is not contested)
  • Patient has an underlying neurological disease or neurological deficit that is not associated with the condition for which he/she is seeking surgical intervention (e.g., diabetic peripheral neuropathy)
  • Patient is participating in another clinical study that would confound study data

Treatment and study plan

Primary outcomes

  1. The sensitivity and specificity of EMG and SSEP (if available) testing in identifying neural injury.

    Time frame: 8 weeks

    For evaluation of the primary endpoint and additional assessments, descriptive statistics including mean, standard deviation, minimum, median, and maximum for continuous variables and frequency distribution for categorical variables will be provided, as well as tabular listings. All complications will be itemized including incidence, duration, and relationship to devices used and/or procedures performed.

Sponsors and collaborators

Lead sponsor

NuVasive

Industry

Registry information

Official study title

Multimodality Neuromonitoring In eXtreme Lateral Interbody Fusion (XLIF®)

Acronym: NV in XLIF®

Important dates

Study start
2011
Primary completion
2013
Study completion
2014
First posted
Dec 26, 2011
Registry last updated
Dec 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.